The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): A multi-center, prospective registry study
Göster/ Aç
Erişim
info:eu-repo/semantics/embargoedAccessTarih
2021Yazar
Soran, AtillaDoğan, Lütfi
Işık, Arda
Özbaş, Serdar
Can Trabulus, Didem
Demirci, Umut
Karanlık, Hasan
Soyder, Aykut
Dağ, Ahmet
Bilici, Ahmet
Doğan, Mutlu
Köksal, Hande
Şendur, Mehmet Ali Nahit
Gülçelik, Mehmet Ali
Maralcan, Göktürk
Cabıoğlu, Neslihan
Yeniay, Levent
Utkan, Zafer
Şimşek, Turgay
Karadurmuş, Nuri
Dağlar, Gül
Yıldız, Birol
Uras, Cihan
Tükenmez, Mustafa
Yıldırım, Ahmet
Kutun, Suat
Özaslan, Cihangir
Karaman, Niyazi
Akçay, Müfide Nuran
Toktaş, Osman
Sezgin, Efe
Üst veri
Tüm öğe kaydını gösterKünye
Soran, A., Doğan, L., Işık, A., Özbaş, S., Can Trabulus, D., Demirci, U. ... Sezgin, E. (2021). The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (Protocol BOMET MF 14-01): A multi-center, prospective registry study. Annals of Surgical Oncology, 28(9), 5048-5057. https://dx.doi.org/10.1245/s10434-021-09621-8Özet
Background More evidence shows that primary surgery for de novo metastatic breast cancer (BC) prolongs overall survival (OS) in selected cases. The aim of this study was to evaluate the role of locoregional treatment (LRT) in BC patients with de novo stage IV bone only metastasis (BOM). Methods The prospective, multicenter registry study BOMET MF14-01 was initiated in May 2014. Patients with de novo stage IV BOM BC were divided into two groups: those receiving systemic treatment (ST group) and those receiving LRT (LRT group). Patients who received LRT were further divided into two groups: ST after LRT (LRT + ST group) and ST before LRT (ST + LRT group). Results We included 505 patients in this study; 240 (47.5%) patients in the ST group and 265 (52.5%) in the LRT group. One hundred and thirteen patients (26.3%) died in the 34-month median follow-up, 85 (35.4%) in the ST group and 28 (10.5%) in LRT group. Local progression was observed in 39 (16.2%) of the patients in the ST group and 18 (6.7%) in the LRT group (p = 0.001). Hazard of death was 60% lower in the LRT group compared with the ST group (HR 0.40, 95% CI 0.30-0.54, p < 0.0001). Conclusion In this prospectively maintained registry study, we found that LRT prolonged survival and decreased locoregional recurrence in the median 3-year follow-up. Timing of primary breast surgery either at diagnosis or after ST provided a survival benefit similar to ST alone in de novo stage IV BOM BC patients.
WoS Q Kategorisi
Q1Scopus Q Kategorisi
Q1Kaynak
Annals of Surgical OncologyCilt
28Sayı
9Koleksiyonlar
- Makale Koleksiyonu [3650]
- PubMed İndeksli Yayınlar Koleksiyonu [4047]
- Scopus İndeksli Yayınlar Koleksiyonu [6283]
- WoS İndeksli Yayınlar Koleksiyonu [6432]